NDLI: Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling

Content Provider	Springer Nature Link
Author	Ge, Guanqun Zhou, Can Ren, Yu Tang, Xiaojiang Wang, Ke Zhang, Wei Niu, Ligang Zhou, Yuhui Yan, Yu He, Jianjun
Copyright Year	2015
Abstract	Even though early detection methods and treatment options are greatly improved, chemoresistance is still a tremendous challenge for breast cancer therapy. Breast cancer stem cells (BCSCs) represent a subpopulation that is central to chemoresistance. We aim to investigate the relationship between SLC34A2 and chemoresistance in BCSCs and identify the underlying mechanisms by which SLC34A2 regulates chemoresistance in BCSCs. Fluorescence Activated Cell Sorting (FACS) analysis showed the presence of a variable fraction of CD44$^{+}$CD24$^{−}$ cells in 25 out of 25 breast cancer samples. We cultured primary breast cancer sample cells and breast cancer cell line cells to induce sphere formation in serum-free medium. Following sorting of CD44$^{+}$CD24$^{−}$ cells from spheres, we showed that CD44$^{+}$CD24$^{−}$ cells displayed stem cell-like features and were resistant to chemotherapy drug doxorubicin. Significantly, enhanced SLC34A2 expression correlated with chemoresponse and survival of breast cancer patients. We subsequently indicated that increased SLC34A2 expression in BCSCs directly contributed to their chemoresistance by a series of in vitro and in vivo experiments. Furthermore, we demonstrated that SLC34A2 induced chemoresistance in BCSCs via SLC34A2-Bmi1-ABCC5 signaling. Finally, we showed that ABCC5 was a direct transcriptional target of Bmi1 by chromatin immunoprecipitation (ChIP). In conclusion, our work indicated that decreased SLC34A2 expression sensitized BCSCs to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling and shed new light on understanding the mechanism of chemoresistance in BCSCs. This study not only bridges the missing link between stem cell-related transcription factor (Bmi1) and ABC transporter (ABCC5) but also contributes to development of potential therapeutics against breast cancer.
Starting Page	5049
Ending Page	5062
Page Count	14
File Format	PDF
ISSN	10104283
Journal	Tumor Biology
Volume Number	37
Issue Number	4
e-ISSN	14230380
Language	English
Publisher	Springer Netherlands
Publisher Date	2015-11-06
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	Breast cancer stem cells CD44$^{+}$CD24$^{−}$ Chemotherapeutic resistance SLC34A2 Bmi1 ABCC5 Cancer Research
Content Type	Text
Resource Type	Article
Subject	Medicine Cancer Research

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.

Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24- breast cancer cells

Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24- breast cancer cells

The Phenotypic Radiation Resistance of CD44 + /CD24 2or low Breast Cancer Cells Is Mediated through the Enhanced Activation of ATM Signaling (2011)

Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells.

The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147+ breast cancer stem cells

Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24- breast cancer cells

Downregulation of cd44 reduces doxorubicin.

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling

Similar Documents

Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.

Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24- breast cancer cells

Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24- breast cancer cells

The Phenotypic Radiation Resistance of CD44 + /CD24 2or low Breast Cancer Cells Is Mediated through the Enhanced Activation of ATM Signaling (2011)

Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells.

The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147+ breast cancer stem cells

Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24- breast cancer cells

Downregulation of cd44 reduces doxorubicin.

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling